Introduction Triple-negative breast cancer (TNBC) presents unique challenges in diagnosis
and treatment. Resveratrol exhibits potential as a therapeutic intervention against TNBC by …

Breast cancer (BC) is a predominant malignancy in women that constitutes approximately
30% of all cancer cases and has a mortality rate of 14% in recent years. The prevailing …

Background Oral mucositis is an inflammatory condition of oral cavity which is a common
and serious side effect of cancer treatment. Severe oral mucositis compromises basic …

Simple Summary Metastatic triple-negative breast cancer is an aggressive cancer with an
average survival of 8 to 13 months. However, survival varies significantly among patients …

Doxorubicin (DOX) is a chemotherapy agent commonly used to treat triple-negative breast
cancer (TNBC), but it has insufficient efficacy against the disease and considerable toxicity …

Triple-negative breast cancer (TNBC) is a highly aggressive type of breast cancer and has a
poor prognosis. As standardized TNBC treatment regimens cause drug resistance and …

The aims of this work were to evaluate the expression of histamine H 3 receptor (H 3 R) in
triple negative breast cancer (TNBC) samples and to investigate the antitumoral efficacy and …

Simple Summary Breast cancer is the most common neoplasm in women. Although the
primary tumor does not appear in a vital organ, lethality is due to the ability of tumor cells to …

Purpose: A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab
(CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall …

Ongoing research is gradually broadening the idea of cancer treatment, with attention being
focused on nanoparticles to improve the stability, therapeutic efficacy, targeting, and other …